Joint position statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on routine testing for latent tuberculosis infection prior to and during treatment of psoriasis patients with interleukin 17 or interleukin 23 inhibitors.
Published by National Psoriasis Foundation Medical Board and the International Psoriasis Council
Summary
AI-generatedAlthough testing for latent tuberculosis (TB) infection has been standard practice for psoriasis patients being treated with interleukin (IL) 17 or IL-23 inhibitors, evidence for this practice is weak.
Key Takeaways
- 1Clinical data suggest that progression of latent tuberculosis infection to active disease during psoriasis treatment with interleukin-17 or interleukin-23 inhibitors is rare.
- 2Experts formulated a new Joint Position Statement, highlighting that testing for latent tuberculosis infection is not required in psoriasis patients being treated with interleukin-17 or interleukin-23 inhibitors.
Key Recommendations
Conclusion
- rec_1
Routine testing for latent TB infection is not required in psoriasis patients being treated with IL-17 or IL-23 inhibitors.
Screening
Scope & Objectives
Clinical Topic
Psoriasis
Objectives
To determine if routine testing for latent tuberculosis infection is required in psoriasis patients treated with IL-17 or IL-23 inhibitors.
Target Patient Population
Psoriasis patients being treated with interleukin-17 or interleukin-23 inhibitors
Target Providers
Patient Criteria & Setting
Therapeutic Area
ImmunologyGuideline Scope
Special Populations
Safety & Contraindications
Monitoring Guidance
Routine testing for latent TB infection is not required prior to and during treatment with IL-17 or IL-23 inhibitors.
Authors & Contributors
Guideline Features
Learning Context
Difficulty
intermediate
Learning Paths